Stock Ratings / Health Care / TRXB / insiders

ZURA (29) KYTX (42) FENC (36) AGMB (51) ⌘ Pro Terminal →

TRex Bio Inc. (TRXB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$13.52 -6.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

TRex Bio Inc. (TRXB) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $371.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-4.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRXB)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

TRXB Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (TRXB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on TRXB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRXB)

✓Walkthrough of TRXB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRXB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.43%

2026-10-30O $13.66H $13.86L $13.10C $13.52VOL 39.2K

SMA50: $14.14

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRXB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRXB Butterfly Map → + Track TRXB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRXB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRXB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRXB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRXB)

Health Care Rank #361 of 1016 ⚔️ ZURA vs TRXB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRXB vs. ZURA, KYTX, FENC, AGMB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, TRex Bio Inc. (TRXB) ranks #361 by composite RQD confidence (49/100, grade D) and #490 by equity capitalization ($371.1M). Within this direct 5-issuer industry benchmark cohort, TRXB leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. AGMB currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with TRXB at 49/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRXB ACTIVE TRex Bio Inc.	D	49/100	—	—	—	-6.31%	$371.1M	Benchmark Subject
ZURA Zura Bio Limited (Class A)	E	29/100	—	—	-35.0%	-11.49%	$370.9M	/zura-vs-trxb →
KYTX Kyverna Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.68%	$361.8M	/kytx-vs-trxb →
FENC Fennec Pharmaceuticals Inc.	D-	36/100	—	—	-25.9%	+0.74%	$383.6M	/fenc-vs-trxb →
AGMB AgomAb Therapeutics NV	D	51/100	—	—	—	-0.13%	$391.5M	/agmb-vs-trxb →

2. TRXB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

TRex Bio Inc. (TRXB) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $371.1M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. TRXB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRXB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, TRex Bio Inc. (NASDAQ: TRXB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $13.52 (-6.31% 1D, market cap $371.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, TRXB ranks #361 in composite RQD confidence.

How does TRXB compare to ZURA and KYTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), TRXB carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZURA (Zura Bio Limited (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $370.9M) and KYTX (Kyverna Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $361.8M). Among the 5-stock peer group, TRXB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRXB?

For TRex Bio Inc. (TRXB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #361 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRXB trading relative to its 50-day, 200-day, and 52-week technical levels?

TRXB last traded at $13.52 (-6.31% on volume of 33,641 shares), positioning the stock -4.79% below its 50-day simple moving average ($14.20) and -2.17% below its 200-day simple moving average ($13.82). Across its 52-week range of $13.10 to $16.56, TRXB sits at the 12.1% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.83 to $15.21).

TRXB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are TRXB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies TRXB leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: TRXB RQD Cockpit TRXB 12M Forecast TRXB Earnings & Move TRXB Dividends & DRIP TRXB Insiders & 13F TRXB Whale Options TRXB Profit Sankey TRXB News & Why